Product Development
Development
Commercialization
- Support and brokerage in product portfolio optimization
Clinical Trials

Study set-up

Study conduct

CSR writing / preparation

Full service Clinical Research Organization

PhV in Clinical Trials
Quality
CMC development
- Nitrosamines
Technology and analytical methods
- Analytical Methods Transfer
GMP system
- GMP system implementation
GxP Audits
GMP
- GMP Audits (remote and on site)
- Audit of manufacturing sites/ laboratory
GCP
- GCP Audits (remote and on site)
PhV
- GVP Audits (remote and on site)
GLP
- GLP Audits (remote and on site)
Regulatory Affairs
Pre-authorisation
- Scientific Advice
- Product information
  
  Preparation of product information
  
  Bridging Report
  
  Package Leaflet readability test
  
  Translation of Patient Information
- Dossier preparation
  
  Medical writing - preparation of registration dossier
  
  CTD Module 3 - Quality
  
  Product information
  
  Enviromental Risk Assessment (ERA)
MA Handling
- Handling of the registration process
Post-authorisation
Regulatory outsourcing

Pharmaceutical law consulting
Pharmacovigilance
PhV system
- Pharmacovigilance system (PSMF)
- RMP Development and maintenance
PhV post-authorisation
Clinical trials
EU QPPV service
QP Service / Importer

QP Service

Import and supply chain management

MIA Certificate

RFI

MENU

pl
en

SciencePharma/

News & Insights

/ Blog /

EMA: New guide on bi...

EMA: New guide on biosimilar medicines for healthcare professionals

The European Medicines Agency (EMA) and the European Commission External link icon have published an information guide for healthcare professionals on biosimilar medicines. Biosimilars are biological medicines that are highly similar in all essential aspects to a biological medicine that has already been authorised.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/05/news_detail_002739.jsp&mid=WC0b01ac058004d5c1

RETURN